Anwaar Saeed, MD

Dr. Saeed summarizes the principal clinical lessons from STELLAR 303 and their implications for the management of refractory MSS metastatic colorectal cancer.

Dr. Saeed describes the rationale and design of STELLAR 316, a three-arm phase 3 trial evaluating zanzalintinib-based therapy in patients with stage III MSS colorectal cancer who test positive for circulating tumor DNA following surgery and adjuvant chemotherapy.

Dr. Saeed and Dr. Ahn address how zanzalintinib plus atezolizumab fits alongside the expanding array of biomarker-targeted therapies in metastatic colorectal cancer.

Dr. Saeed and Dr. Ahn examine the safety data from STELLAR 303 and discuss practical strategies for managing toxicity in clinical practice.

Dr. Saeed presents the design and primary efficacy results of STELLAR 303, the phase 3 trial evaluating zanzalintinib plus atezolizumab versus regorafenib in patients with chemorefractory MSS metastatic colorectal cancer.

Dr. Saeed and Dr. Ahn review what has been learned from early phase trials examining multi-kinase inhibitors combined with immune checkpoint inhibitors in MSS metastatic colorectal cancer, including LEAP-017 and COSMIC-021.

Dr. Saeed and Dr. Ahn discuss the biologic features that make non-MSI-high colorectal cancer resistant to immune checkpoint inhibition and the scientific rationale for combining multi-kinase inhibitors with immunotherapy.

Anwaar Saeed, MD, and Daniel Ahn, MD, open this OncLive Insights program with an overview of the current treatment landscape for patients with non-MSI-high metastatic colorectal cancer who have progressed on standard chemotherapy, including fluoropyrimidine-, oxaliplatin-, and irinotecan-based regimens.

Anwar Saeed, MD, discusses the rationale behind the STELLAR-303 trial evaluating zanzalintinib plus atezolizumab vs regorafenib in pretreated mCRC

To close, Dr. Saeed and Dr. Singal share their excitement for the future landscape, emerging agents and treatment strategies for patients with HCC.

Drs Saeed and Singal discuss additional data presented at AASLD 2023 related to frontline systemic therapies and emerging combinations in unresectable HCC.

Expert oncologists review real-world data and discuss the impact on treatment selection in uHCC.

An expert analysis in data surrounding treatment outcomes in combination regimens, noting immune-mediate adverse events and overall impact on treatment response.

Dr. Saeed outlines the use of combination tremelimumab plus durvalumab in uHCC, discussing updates from the HIMALAYA trial presented at AASLD 2023.

A comprehensive review of clinical data of atezolizumab plus bevacizumab for the treatment of unresectable HCC.

Anwaar Saeed, MD, and Amit Singal, MD, discuss the evolving treatment landscape for hepatocellular carcinoma, highlighting FDA approvals and the utility of clinical biomarkers.

Anwaar Saeed, MD, discusses biomarkers that signal the potential efficacy of frontline immunotherapy regimens in patients with advanced esophageal squamous cell carcinoma.